Parkman Healthcare Partners LLC Sells 9,309 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Parkman Healthcare Partners LLC cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 100,159 shares of the biopharmaceutical company's stock after selling 9,309 shares during the period. Parkman Healthcare Partners LLC owned about 0.11% of Ultragenyx Pharmaceutical worth $4,214,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Hudson Bay Capital Management LP boosted its position in Ultragenyx Pharmaceutical by 93.6% during the fourth quarter. Hudson Bay Capital Management LP now owns 377,500 shares of the biopharmaceutical company's stock valued at $15,881,000 after buying an additional 182,500 shares during the period. Graham Capital Management L.P. boosted its position in Ultragenyx Pharmaceutical by 37.5% during the fourth quarter. Graham Capital Management L.P. now owns 59,129 shares of the biopharmaceutical company's stock valued at $2,488,000 after buying an additional 16,128 shares during the period. D. E. Shaw & Co. Inc. boosted its position in Ultragenyx Pharmaceutical by 9.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 286,079 shares of the biopharmaceutical company's stock valued at $12,035,000 after buying an additional 24,485 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Ultragenyx Pharmaceutical by 17.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 346,597 shares of the biopharmaceutical company's stock valued at $14,581,000 after buying an additional 51,874 shares during the period. Finally, Driehaus Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 5.8% during the fourth quarter. Driehaus Capital Management LLC now owns 829,465 shares of the biopharmaceutical company's stock valued at $34,896,000 after buying an additional 45,521 shares during the period. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now directly owns 54,991 shares in the company, valued at approximately $2,358,014.08. The trade was a 5.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emil D. Kakkis sold 73,434 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the completion of the sale, the chief executive officer now owns 641,731 shares in the company, valued at approximately $27,016,875.10. This represents a 10.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 125,405 shares of company stock worth $5,285,169. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock traded up $0.24 on Monday, hitting $35.85. 278,033 shares of the company's stock were exchanged, compared to its average volume of 824,059. The company has a 50-day simple moving average of $36.39 and a 200-day simple moving average of $41.64. The stock has a market capitalization of $3.39 billion, a PE ratio of -5.67 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 1 year low of $29.59 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same quarter in the prior year, the business earned ($2.03) EPS. The company's revenue was up 28.0% compared to the same quarter last year. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on RARE. HC Wainwright reaffirmed a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Morgan Stanley raised their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Piper Sandler reduced their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $90.93.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.